Ainos, Inc. (NASDAQ:AIMD)

Ainos, Inc. AIMD

Healthcare - Biotechnology - NASDAQ - US

Watchlist

$ 0.5496

-2 %

$ 8.48 M

Market Cap

-0.35

P/E

1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one AIMD stock under the worst case scenario is HIDDEN Compared to the current market price of 0.55 USD, Ainos, Inc. is HIDDEN

AIMD Intrinsic Value
HIDDEN

SHOW

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one AIMD stock under the base case scenario is HIDDEN Compared to the current market price of 0.55 USD, Ainos, Inc. is HIDDEN

AIMD Intrinsic Value
HIDDEN

SHOW

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one AIMD stock under the best case scenario is HIDDEN Compared to the current market price of 0.55 USD, Ainos, Inc. is HIDDEN

AIMD Intrinsic Value
HIDDEN

SHOW

2. FUNDAMENTAL ANALYSIS

Price Chart AIMD

FINANCIALS

Annual
Quarterly

-13.8 M OPERATING INCOME

-5.81 M OPERATING CASH FLOW

-125 K INVESTING CASH FLOW

8.03 M FINANCING CASH FLOW

-4.63 M OPERATING INCOME

-864 K OPERATING CASH FLOW

13.3 K INVESTING CASH FLOW

-270 K FINANCING CASH FLOW

Balance Sheet Ainos, Inc.

28.8 M ASSETS
13.3 M LIABILITIES

Current Assets	4.34 M
Cash & Short-Term Investments	3.89 M
Receivables	56
Other Current Assets	445 K
Non-Current Assets	24.5 M
Long-Term Investments	0
PP&E	560 K
Other Non-Current Assets	23.9 M

Current Liabilities	3.95 M
Accounts Payable	0
Short-Term Debt	3 M
Other Current Liabilities	955 K
Non-Current Liabilities	9.35 M
Long-Term Debt	9 M
Other Non-Current Liabilities	349 K

EFFICIENCY

Earnings Waterfall Ainos, Inc.

Revenue	20.7 K
Cost Of Revenue	52.6 K
Gross Profit	-31.9 K
Operating Expenses	13.8 M
Operating Income	-13.8 M
Other Expenses	1.02 M
Net Income	-14.9 M

RATIOS

-153.73% GROSS MARGIN

-66772.17% OPERATING MARGIN

-71702.26% NET MARGIN

FREE CASH FLOW ANALYSIS

Free Cash Flow Analysis Ainos, Inc.

Net Income	-14.9 M
Depreciation & Amortization	4.8 M
Capital Expenditures	-21.3 K
Stock-Based Compensation	3.54 M
Change in Working Capital	37.1 K
Others	686 K
Free Cash Flow	-5.83 M

3. WALL STREET ANALYSTS ESTIMATES

Wall Street Analysts Price Targets Ainos, Inc.

AIMD has no price targets from Wall Street.

4. DIVIDEND ANALYSIS

AIMD does not distribute dividends.

5. COMPETITION

Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo.

12.2 USD

AORT

Overvalued 47.78%

Tenon Medical, Inc., a medical device company, develops surgical implant systems to optimize sacroiliac joint fixation/fusion surgery and corresponding outcomes. It sells The CATAMARAN SIJ Fusion System that includes instruments and implants designed to prepare and fixate the SI-Joint for fusion in the United States and Puerto Rico.

-237 USD

TNON

Overvalued 20898.32%

STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America.

-7.09 USD

SSKN

Overvalued 364.79%

NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source.

-47.8 USD

NPCE

Overvalued 550.32%

Movano Inc. engages in developing a platform to deliver healthcare solutions at the intersection of medtech and consumer devices. Its platform uses radiofrequency technology, which enables the creation of sensors that are small enough to fit into wearable devices and other small form factors.

-55.3 USD

MOVE

Overvalued 7013.77%

OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally.

-123 USD

KIDS

Overvalued 691.35%

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally.

-1.85 USD

ANIK

Overvalued 113.03%

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF.

6. Ownership

Insider Ownership Ainos, Inc.

Summary
Transactions

Sold

0-3 MONTHS

0 USD 0

3-6 MONTHS

0 USD 0

6-9 MONTHS

0 USD 0

9-12 MONTHS

0 USD 0

Bought

2.25 M USD 1

0-3 MONTHS

0 USD 0

3-6 MONTHS

0 USD 0

6-9 MONTHS

0 USD 0

9-12 MONTHS

Date	Value	Insider	Amount	Avg Price
1 month ago Mar 10, 2025	Bought 2.25 M USD	ASE Test, Inc. 10 percent owner	+ 499377	4.5 USD
12 years ago Jun 01, 2012	Bought 20 USD	Paul Tibbits director, 10 percent owner:	+ 1000	0.02 USD
12 years ago Jun 18, 2012	Sell 275 USD	MOORE DENNIS DEAN Director	- 10000	0.0275 USD
12 years ago Jun 20, 2012	Sell 183 USD	MOORE DENNIS DEAN Director	- 10000	0.0183 USD
12 years ago May 30, 2012	Bought 1.96 USD	Paul Tibbits director, 10 percent owner:	+ 98	0.02 USD
12 years ago May 30, 2012	Bought 1.96 USD	Paul Tibbits director, 10 percent owner:	+ 98	0.02 USD
12 years ago May 31, 2012	Bought 4 K USD	Paul Tibbits director, 10 percent owner:	+ 200000	0.02 USD
12 years ago May 31, 2012	Bought 500 USD	Paul Tibbits director, 10 percent owner:	+ 25000	0.02 USD
13 years ago Apr 04, 2012	Bought 175 USD	Paul Tibbits director, 10 percent owner:	+ 5000	0.035 USD
13 years ago Apr 10, 2012	Bought 5.44 K USD	Paul Tibbits director, 10 percent owner:	+ 155500	0.035 USD

7. News

Ainos and ugo Complete First Robotic Smell Integration in Japan Milestone Ignites a New Era of Smell-Enabled Robotics Installs AI Nose in ugo Robot; Real-World Pilots to Begin in Weeks SAN DIEGO, CA / ACCESS Newswire / April 21, 2025 / Ainos, Inc. (Nasdaq:AIMD)(Nasdaq:AIMDW) ("Ainos"), a leader in AI-powered scent digitization, has successfully installed its proprietary AI Nose olfaction module on a humanoid robot developed by ugo, Inc. ("ugo"), Japan's top service robotics company. Completed on April 9, 2025, the installation marks the world's first robot with a functional sense of smell, a breakthrough that redefines the frontier of robotics, AI, and human-machine interaction. accessnewswire.com - 1 week ago

Ainos Secures TFDA Approval and IRB Clearance to Advance VELDONA Clinical Trials for HIV Oral Warts and Sjögren's Syndrome in Taiwan Dual Trials Accelerate VELDONA® Toward Rare Disease Market Entry Bridging Strategy Aims to Fast-Track U.S. Regulatory Approvals SAN DIEGO, CALIFORNIA / ACCESS Newswire / April 14, 2025 / Ainos, Inc. (Nasdaq:AIMD, AIMDW) ("Ainos" or the "Company"), pioneer of low-dose oral interferon therapeutics, today announced significant progress in advancing its oral interferon drug platform, VELDONA® in the rare disease space. The Taiwan Food and Drug Administration (TFDA) has approved the Company's clinical trial for human immunodeficiency virus (HIV)-related oral warts, while Institutional Review Board (IRB) clearance has been granted for its upcoming Sjögren's Syndrome (pSS) study. accessnewswire.com - 2 weeks ago

Water Tower Research Highlights Ainos' AI Nose Expansion into Robotics and Semiconductor Manufacturing - Smell ID Is Scaling Strategic partnerships and industry-leading accuracy position Ainos as a game-changer in digitized scent technology SAN DIEGO, CALIFORNIA / ACCESS Newswire / April 11, 2025 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos" or the "Company"), a leader in AI-powered scent digitization, today announced that Water Tower Research ("WTR") has published a report spotlighting the Company's expansion of its AI Nose technology into the robotics and semiconductor sectors. The report features insights from a management fireside chat on April 8, 2025. accessnewswire.com - 3 weeks ago

Ainos to Participate in Fireside Chat with Water Tower Research on April 8, 2025 SAN DIEGO, CALIFORNIA / ACCESS Newswire / March 24, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a leader in AI-powered scent digitization, today announced that it will participate in a fireside chat with Do Kim, senior research analyst of Water Tower Research ("WTR") and John Roy, managing director of WTR on Tuesday, April 8, 2025, at 10:00 a.m. ET. Ainos will provide insights into AI Nose applications, including its use in smart manufacturing and robots, as well as the impact of AI-driven digitized smell on industries beyond healthcare. accessnewswire.com - 1 month ago

Water Tower Research Spotlights Ainos & ASE Partnership: Unleashing AI Nose's Potential in Chip Manufacturing and More Another key win in expanding AI Nose's industrial opportunities Partnership to integrate AI Nose into ASE's factories and explore broader industrial use-cases SAN DIEGO, CALIFORNIA / ACCESS Newswire / March 13, 2025 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos" or the "Company"), a leader in AI-powered scent digitization, today announced that Water Tower Research ("WTR") has published a report spotlighting Ainos' strategic collaboration with Advanced Semiconductor Engineering, Inc. ("ASE"), the world's largest provider of semiconductor packaging and testing services. The partnership will integrate Ainos' AI Nose, an AI-powered electric nose technology, into ASE's factories, expanding AI Nose's opportunity in semiconductor manufacturing. accessnewswire.com - 1 month ago

Ainos and ASE Partner to Power AI Scent Digitization in Semiconductor Manufacturing Harnessing AI-Powered Scent Digitization for Smarter, Safer, and More Sustainable Factories SAN DIEGO, CA / ACCESS Newswire / March 11, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a leader in AI-driven scent digitization, has announced a strategic collaboration with Advanced Semiconductor Engineering, Inc. (ASE), the world's largest provider of semiconductor packaging and testing services. This partnership aims to revolutionize semiconductor manufacturing by leveraging Ainos' patented AI Nose technology to analyze airborne chemicals into "Smell IDs", enhancing process efficiency, environmental safety, and environmental, social, and governance (ESG) compliance. accessnewswire.com - 1 month ago

Ainos Reports Full Year 2024 Financial Results Unveiled revolutionary AI Nose for robotics application, inviting global robotics companies to join Ainos Alliance in shaping the future of smell-enabled robots Advanced VELDONA® development with key Japan patent, Taiwan Tanabe partnership, and IRB approval for Sjögren's syndrome clinical study SAN DIEGO, CALIFORNIA / ACCESS Newswire / March 7, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQAIMDW) ("Ainos", or the "Company") today announced its financial results for the fiscal year ended December 31, 2024. Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "2024 marked another pivotal year as we transitioned from our COVID-19 antigen rapid test business to advancing the VELDONA® and pioneering AI Nose programs. accessnewswire.com - 1 month ago

Water Tower Research Highlights Ainos & ugo Partnership: The Final Sense for Robots - AI Smell is Here Practical partnership for AI Nose, multiple new opportunities AI Nose to change robotics landscape with first AI smell sensing SAN DIEGO, CA / ACCESS Newswire / March 7, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a pioneer of smell digitization, today announced that Water Tower Research ("WTR") has published a report on the Company's strategic partnership with ugo, Inc., a leading Japanese service robotics company. The collaboration will integrate Ainos' innovative AI Nose technology into ugo's service robots, marking a milestone in digitizing olfactory sensing. accessnewswire.com - 1 month ago

Ainos and ugo to Develop the World's First Robot With a Sense of Smell A Major Breakthrough in Ainos' Mission to Digitize Scent First-ever Smell-Enabled Robotics Will Unlock New Revenue Streams in Smart Manufacturing, Public Safety and more SAN DIEGO, CA / ACCESS Newswire / March 5, 2025 / Ainos, Inc. (Nasdaq:AIMD)(Nasdaq:AIMDW), a pioneer of smell digitization, and ugo, Inc., Japan's largest service robot company by market share1, today announced a strategic partnership to integrate Ainos' AI Nose technology with ugo's autonomous robotic platform. This collaboration will mark a major milestone in the digitization of smell, unlocking new capabilities for robots in industrial safety, healthcare, and public security. accessnewswire.com - 1 month ago

Ainos Achieves Major Breakthrough: Japan Patent Approval for VELDONA Redefines Antiviral Innovation Revolutionary Oral Interferon Technology Combines Unmatched Advantages and Global Potential in the $16 Billion Coronavirus Market SAN DIEGO, CA / ACCESS Newswire / January 27, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") proudly announces the granting of a pivotal invention patent in Japan (Patent No. 7619659) for its groundbreaking oral interferon formulation, VELDONA®, to treat and prevent coronavirus infections. accessnewswire.com - 3 months ago

Water Tower Research Spotlights Ainos' AI Nose Programs and Strategic Milestones for 2025 Report highlights greater visibility in AI Nose developments, including robotics, smart manufacturing, elderly care monitoring, and women's health testing SAN DIEGO, CA / ACCESS Newswire / January 21, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a pioneer of digiting scent and low-dose interferon therapeutics, today announced that Water Tower Research ("WTR") has published a report projecting increased visibility for the Company's transformative AI Nose programs. The report emphasizes anticipated progress for AI Nose across multiple sectors, including robotics, smart manufacturing, elderly care, and women's health. accessnewswire.com - 3 months ago

Ainos Granted 180-Day Extension by Nasdaq to Regain Compliance With Minimum Bid Price Rule SAN DIEGO, CA / ACCESS Newswire / January 17, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), today announced that it had received written notification (the "Written Notification") from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") that the Company is eligible for a 180-day extension to regain compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Rule"). As previously reported, on July 15, 2024, the Company received a deficiency letter from the Nasdaq notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company's common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to the Rule and the Company had been given 180 calendar days, or until January 13, 2025, to regain compliance with the Rule. accessnewswire.com - 3 months ago

8. Profile Summary

Ainos, Inc. AIMD

COUNTRY US

INDUSTRY Biotechnology

MARKET CAP $ 8.48 M

Dividend Yield 0.00%

Description Ainos, Inc., a healthcare company, engages in the developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. Ainos, Inc. was incorporated in 1984 and is based in San Diego, California.

Contact 8880 Rio San Diego Drive, San Diego, CA, 92108 https://ainos.com

IPO Date Jan. 8, 2021

Employees 44

Officers Mr. Hsin-Liang Lee Chief Financial Officer Mr. Chih-Heng Lu Director of Corporate Developoment Mr. Chun-Hsien Tsai Chief Executive Officer, President & Chairman of the Board

Price Chart AIMD

Ainos, Inc. AIMD

Free

Unlimited Plan

Premium Plan